In HCC, IGF2BP1 not only reduces the infiltration of immune cells, such as CD4+ and CD8+ T cells, CD56+ natural killer cells, and F4/80+ macrophages but also increases the expression of programmed death-ligand 1 (PD-L1), which indicates that IGF2BP1 may act as a new anti-tumor therapeutic target by disrupting the tumor immune microenvironment 73. The gene discussed is IGF2BP1; the disease is neoplasm.